Ananta Medicare Ukraine Limited Pharmaceutical Import Profile — Ukraine (DGFT 2022–2026)

Name: Ananta Medicare Ukraine Limited Pharmaceutical Import Records from India — 2 Products, $1.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ananta Medicare Ukraine Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $1.9M Trade | TransData Nexus

Ananta Medicare Ukraine Limited

Pharmaceutical Importer · Ukraine · Advanced Antibiotics Focus · $1.9M Total Trade · DGFT Verified

Ananta Medicare Ukraine Limited is a pharmaceutical importer based in Ukraine with a total trade value of $1.9M across 2 products in 1 therapeutic categories. Based on 37 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Ananta Medicare Ukraine Limited sources from 1 verified Indian supplier, with Ananta Medicare Limited accounting for 100.0% of imports.

Ananta Medicare Ukraine Limited — Import Portfolio & Supplier Network

Ananta Medicare Ukraine Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ananta Medicare Ukraine Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ananta Medicare Limited	$370.3K	10	100.0%

Ananta Medicare Ukraine Limited sources from 1 verified Indian supplier across 10 distinct formulations. The sourcing is highly concentrated — Ananta Medicare Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Ananta Medicare Ukraine Limited Import?

Formulation	Value	Ships
Esozol lyophilized powder for	$50.0K	1
Ceftazidime 1g-ceftazidime with sodiumcarbonate USP florazide powder for solution for 1g in vial	$50.0K	1
Ceftazidime 1g- ceftazidime with sodiumcarbonate USP denizid powder for solution for 1g in vial	$50.0K	1
Sterile ceftriaxone sodium USP-efmerinpowder for solution for 1g in vial	$50.0K	1
Cefepime hcl+l arginine sterile USP- denepime powder for solution for 1g in vial	$50.0K	1
Cefepime hcl+l arginine sterile USP- cefotrine powder for solution for 1g in vial	$50.0K	1
Sterile ceftriaxone sodium USP-efmerinpowder for solution for 2g in vial	$50.0K	1
Ceftazidime powder for solution 1 g invial no.1 batch no:03231201mfg dt:12/2023 exp	$14.4K	1
Ceftriaxone ananta powder for solution 1 g in vial no.1bt no:29240101 mfg dt:01/2024exp	$4.0K	1
Ayurvedic product-borosan cream 25 g no.1 batch no.2623091 manufacturing dt.09/2023	$1.8K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ceftriaxone	Advanced Antibiotics	$950.0K	19	0.3%	11
2	Ceftazidime	Advanced Antibiotics	$900.0K	18	7.0%	2

Ananta Medicare Ukraine Limited imports 2 pharmaceutical products across 1 categories into Ukraine totaling $1.9M.

Ananta Medicare Ukraine Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ananta Medicare Ukraine Limited is a pharmaceutical importer and distributor based in Kharkiv, Ukraine. Established on May 14, 2021, the company operates as a subsidiary of Ananta Medicare Limited, an Indian pharmaceutical manufacturer founded in 1999 by Mr. Pradeep Kumar Jain. Ananta Medicare Limited specializes in the manufacturing, marketing, and distribution of medicines, dietary supplements, and cosmetics, with a focus on natural ingredients. The parent company owns three modern pharmaceutical plants in Sriganganagar, Rajasthan, India, and has registered offices in the United Kingdom, India, and Ukraine.

Ananta Medicare Ukraine Limited plays a significant role in Ukraine's pharmaceutical distribution network by importing and distributing finished pharmaceutical formulations from India. The company's operations are integral to ensuring the availability of quality pharmaceutical products in the Ukrainian market, particularly in the therapeutic category of advanced antibiotics. By leveraging its connection with Ananta Medicare Limited, the Ukrainian subsidiary benefits from a robust supply chain and access to a diverse portfolio of pharmaceutical products.

2Distribution Network

Ananta Medicare Ukraine Limited's distribution network is centered in Kharkiv, where it maintains its primary operations. The company imports finished pharmaceutical formulations from India, focusing on advanced antibiotics, and distributes these products across Ukraine. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's affiliation with Ananta Medicare Limited suggests access to well-established supply chain infrastructure. This infrastructure likely includes modern storage facilities and efficient distribution channels, ensuring timely delivery of pharmaceutical products to various regions within Ukraine.

3Industry Role

Ananta Medicare Ukraine Limited functions as a pharmaceutical importer and distributor within Ukraine's pharmaceutical supply chain. By sourcing finished pharmaceutical formulations from India, the company serves as a conduit between Indian manufacturers and the Ukrainian market. Its role is crucial in ensuring the availability of specific pharmaceutical products, particularly in the advanced antibiotics category, thereby contributing to the overall healthcare landscape in Ukraine.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ananta Medicare Ukraine Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ananta Medicare Ukraine Limited exhibits a high degree of supplier concentration, sourcing 100% of its imported pharmaceutical products from a single supplier, Ananta Medicare Limited in India. This single-source dependency indicates a strategic choice to maintain a consistent supply of quality products from a trusted manufacturer. The shipment data reveals a stable relationship, with 37 shipments valued at $1.9 million USD over the period from 2022 to 2026. The top two products imported are Ceftriaxone and Ceftazidime, accounting for 100% of the company's imports in the advanced antibiotics category. This concentration suggests a focused product strategy, potentially streamlining operations and quality control processes.

2Supply Chain Resilience

The resilience of Ananta Medicare Ukraine Limited's supply chain is closely tied to its exclusive sourcing from Ananta Medicare Limited in India. While this single-source strategy ensures product consistency and quality, it also exposes the company to risks associated with supply chain disruptions in India. The lack of publicly available information regarding backup suppliers and formulation diversity indicates a potential vulnerability. Additionally, the company's reliance on a single shipping route and the regulatory compliance of its key supplier are critical factors influencing supply chain resilience. To enhance resilience, diversifying suppliers and formulations, as well as establishing alternative shipping routes, could be considered.

Importing Pharmaceuticals into Ukraine — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Ukraine

1Regulatory Authority & Framework

In Ukraine, the State Agency of Ukraine for Pharmaceutical Products is the primary regulatory body overseeing the import and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Law of Ukraine on Pharmaceutical Products No. 123/96-ВР, dated April 4, 1996, and its subsequent amendments. The marketing authorization pathway for Indian generics involves obtaining an import license from the State Agency of Ukraine for Pharmaceutical Products, ensuring compliance with Ukrainian pharmaceutical regulations. (cms.law)

2Import Licensing & GMP

Import licensing requirements in Ukraine stipulate that importers of pharmaceutical products must obtain a separate import license from the State Agency of Ukraine for Pharmaceutical Products. This license is granted to importers who meet specific criteria, including possessing sufficient material and technical resources. Good Manufacturing Practice (GMP) certificates recognized by the State Agency of Ukraine for Pharmaceutical Products are essential for ensuring product quality and safety. Importers must ensure that their suppliers hold valid GMP certifications to comply with Ukrainian regulations. (cms.law)

3Quality & Labeling

Ananta Medicare Ukraine Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ananta Medicare Ukraine Limited's focus on importing advanced antibiotics, specifically Ceftriaxone and Ceftazidime, aligns with the therapeutic needs of the Ukrainian market. The high import values and market shares of these products indicate strong demand and a strategic emphasis on addressing critical healthcare needs. This product strategy reflects a commitment to providing essential medications that meet the therapeutic requirements of healthcare providers and patients in Ukraine.

2Sourcing Profile

Ananta Medicare Ukraine Limited's sourcing strategy centers on importing generic drugs, particularly in the advanced antibiotics category, from its parent company, Ananta Medicare Limited in India. The focus on finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), suggests a preference for ready-to-market products that comply with Ukrainian regulatory standards. This approach streamlines the procurement process and ensures product quality and consistency.

3Market Positioning

Based on its product mix, Ananta Medicare Ukraine Limited primarily serves the hospital and wholesale distribution segments of the Ukrainian pharmaceutical market. The emphasis on advanced antibiotics positions the company to meet the needs of healthcare institutions requiring these critical medications. By focusing on high-demand therapeutic areas, the company strengthens its presence in the healthcare supply chain, contributing to the overall efficacy of medical treatments in Ukraine.

Seller's Guide — How to Become a Supplier to Ananta Medicare Ukraine Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Ukrainian market by meeting the specific product requirements and quality standards of Ananta Medicare Ukraine Limited. Gaps in the company's current sourcing, such as the potential for diversifying product formulations or expanding into additional therapeutic categories, present avenues for collaboration. Establishing direct communication and demonstrating compliance with Ukrainian regulatory standards are essential steps for potential suppliers seeking to become alternative sources for Ananta Medicare Ukraine Limited.

2Requirements & Qualifications

Indian exporters aiming to supply Ananta Medicare Ukraine Limited and the Ukrainian market must obtain GMP certifications recognized by the State Agency of Ukraine for Pharmaceutical Products. Additionally, compliance with Ukrainian import licensing requirements, including obtaining a separate import license, is mandatory. Ensuring that products meet Ukrainian quality and labeling standards, including batch testing and stability requirements, is crucial for market acceptance.

3How to Approach

Frequently Asked Questions — Ananta Medicare Ukraine Limited

What products does Ananta Medicare Ukraine Limited import from India?

Ananta Medicare Ukraine Limited imports 2 pharmaceutical products across 1 categories. Top imports: Ceftriaxone ($950.0K), Ceftazidime ($900.0K).

Who supplies pharmaceuticals to Ananta Medicare Ukraine Limited from India?

Ananta Medicare Ukraine Limited sources from 1 verified Indian suppliers. The primary supplier is Ananta Medicare Limited (100.0% of imports, $370.3K).

What is Ananta Medicare Ukraine Limited's total pharmaceutical import value?

Ananta Medicare Ukraine Limited's total pharmaceutical import value from India is $1.9M, based on 37 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ananta Medicare Ukraine Limited focus on?

Ananta Medicare Ukraine Limited imports across 1 categories. The largest: Advanced Antibiotics (100.0%).

Get Full Ananta Medicare Ukraine Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.